Evolent Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Evolent Health, Inc.'s 2022 Annual Meeting of Stockholders held on June 9, 2022. The filing details the voting outcomes for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals with the following outcomes:
- Proposal 1 (Election of Directors): All seven Class I and Class III director nominees were elected. Votes ranged from approximately 73 million to 79 million "For" votes. Notable "Against" votes included 6.66 million for David Farner and 4.94 million for Frank Williams.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote was 83,603,510 "For" versus 30,952 "Against."
- Proposal 3 (Executive Compensation): Stockholders approved the 2021 compensation of named executive officers on an advisory basis. The vote was 77,483,402 "For" versus 2,838,763 "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the higher "Against" vote counts for directors David Farner and Frank Williams compared to other nominees.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the definitive proxy statement (Schedule 14A) filed on April 29, 2022, for detailed biographies of the elected directors and the full compensation discussion for Proposal 3.